In Vitro Diagnostics Alliances from Elsevier Business Intelligence

[Hitachi High-Technologies] to sell [Nanosphere]'s diagnostics in Japan

Tue, 14 May 2013 19:00:47 -0400

[Hitachi Ltd.]’s [Hitachi High-Technologies Corp.] has received exclusive rights to market molecular diagnostics firm [Nanosphere Inc.]’s products in Japan.

[Amgen] teams up with [Transgenomic] to develop a colorectal cancer test

Thu, 09 May 2013 19:01:16 -0400

[Amgen Inc.] has penned a deal with [Transgenomic Inc.] (diagnostics) to develop a CE-IVD test to screen metastatic colorectal cancer patients for RAS mutations.

[Core Diagnostics] to market [CardioDx]'s {Corus} test in India

Thu, 09 May 2013 19:01:00 -0400

[Core Diagnostics India] has licensed exclusive Indian rights to fellow molecular diagnostics firm [CardioDx Inc.]’s {Corus}, a noninvasive blood-based gene expression test for patients with symptoms of obstructive coronary artery disease (CAD).

[NanoString] takes an option to exclusively license a liver cancer gene signature from the [Broad Institute]

Fri, 26 Apr 2013 19:01:00 -0400

The [Broad Institute] has granted life sciences company [NanoString Technologies Inc.] an option to license exclusive worldwide rights to a 186-gene signature that could be used to determine the prognosis of patients with hepatocellular carcinoma (HCC) or hepatitis C-related early-stage cirrhosis.

[Bayer], [DKFZ] jointly invest €3.5mm in cancer drug development; deal later expanded

Thu, 25 Apr 2013 19:02:03 -0400

[Bayer Schering Pharma AG] and the [German Cancer Research Center] (DKFZ) have formed a two-year partnership to discover novel cancer treatments.

[Abbott Molecular] to create companion diagnostic for [Epizyme]'s cancer compound

Thu, 18 Apr 2013 19:01:00 -0400

[Abbott Molecular Inc.] will create a companion molecular diagnostic for use with personalized cancer therapies developer [Epizyme Inc.]’s lead compound, Phase I EPZ5676.

[OncoMethylome], [Roche] partner to develop diagnostic for personalized cancer treatment

Tue, 09 Apr 2013 19:02:15 -0400

[OncoMethylome Sciences SA] (molecular diagnostics using PCR-based DNA methylation) will use its MGMT (methylguanine-DNA methyltransferase) gene promoter methylation assay to determine glioblastoma multiforme (GBM) patients who will benefit from treatment with [Roche]’s Phase III {Avastin} (bevacizumab). This Roche antibody candidate works by inhibiting VEGF (vascular endothelial growth factor), which plays a key role in tumor angiogenesis.

[Sequoia Genetics] teams up with [Research Centre of Medical Genetics] to create neonatal diagnostics

Tue, 09 Apr 2013 19:02:07 -0400

[Alkor Bio Group]’s [Sequoia Genetics] (molecular diagnostics) will work with the [Russian Academy of Medical Sciences]’ [Research Centre of Medical Genetics] (RCMG) to develop diagnostics to detect inherited diseases in newborns and determine the carrier status of couples planning a family.

[Neurotrope] gets diagnostic/therapeutic Alzheimer’s IP from [BRNI]

Fri, 05 Apr 2013 19:01:00 -0400

[West Virginia University]’s [Blanchette Rockefeller Neuroscience Institute] (BRNI) has licensed its neurodegenerative disease technologies to start-up [Neurotrope BioScience Inc.], which plans to develop them into diagnostics and therapeutics initially for Alzheimer’s disease (AD). The company will have global commercial rights to resulting products.

[Miraculins] gets exclusive license to high-risk pregnancy biomarker from [Mount Sinai Hospital]

Fri, 05 Apr 2013 19:01:00 -0400

[Mount Sinai Hospital of Toronto]’s [Samuel Lunenfeld Research Institute] (SLRI) has granted diagnostics firm [Miraculins Inc.] a license to methods and reagents to detect hydroxylated hypoxia inducible factor 1 alpha (HIF-1aOH), a preclinical biomarker to determine high-risk pregnancies, including preeclampsia.

[Luminex] develops a companion test for [Merck]'s Alzheimer's candidate MK8931

Thu, 21 Mar 2013 19:01:32 -0400

[Luminex Corp.] (multiplex diagnostics systems) has agreed to work with [Merck & Co. Inc.] to develop a companion diagnostic for the Big Pharma’s lead Phase II Alzheimer’s candidate MK8931. Luminex is responsible for all development, regulatory activities, and commercialization of the test.

[Fosun Pharma] will sell [Saladax]'s {MyCare} cancer assays in China

Thu, 21 Mar 2013 19:01:20 -0400

[Saladax Biomedical Inc.] (diagnostics for personalized medicine) has chosen Chinese biopharma company [Shanghai Fosun Pharmaceutical Group Co. Ltd.] (Fosun Pharma) and its diagnostics division [Shanghai Fosun Long March Medical Science Co. Ltd.] to exclusively manufacture and sell its {MyCare} line of chemotherapy dose management assays in China.

[Oxford Gene Technology] licenses microRNA biomarkers from the [Institute of Cancer Research]

Wed, 20 Mar 2013 19:01:47 -0400

Genetics research and biomarker discovery company [Oxford Gene Technology Ltd.] (OGT) has licensed rights from the [Institute of Cancer Research] (ICR) to develop and sell a set of diagnostic and prognostic microRNA biomarkers for prostate cancer.

[Psychemedics] to market [TruTouch]’s workplace sobriety test in the US

Fri, 15 Mar 2013 19:01:15 -0400

[TruTouch Technologies Inc.] (alcohol detection) has licensed hair-based drug testing firm [Psychemedics Corp.] exclusive US rights to market its TruTouch 2500 workplace sobriety diagnostic.

[Handok] to sell [NeuroMetrix]’s {NC-stat DPNCheck} diabetic neuropathy test in South Korea

Thu, 14 Mar 2013 19:02:18 -0400

[NeuroMetrix Inc.] (diagnosis and treatment of diabetic neuropathies) has licensed [Handok Pharmaceuticals Co. Ltd.] (sells drugs, diagnostics, and devices in South Korea) exclusive rights to market in the Republic of Korea (South Korea) its {NC-stat DPNCheck} early-stage diagnostic for diabetic peripheral neuropathy.

[Alpha Szenszor] partners with [Technion Israel] to develop exhaled-breath lung cancer diagnostic

Thu, 14 Mar 2013 19:02:09 -0400

[Alpha Szenszor Inc.] (carbon nanotube sensor technology for life science applications) has chosen the [Technion Israel Institute of Technology] as its first partner in the development of a breath-based diagnostic for lung cancer.

[Partners & Partners] to exclusively distribute [Aviir]'s products

Thu, 14 Mar 2013 19:02:00 -0400

Medical distributor [Partners & Partners LLC] has agreed to be the sole distributor of cardiovascular diagnostics firm [Aviir Inc.]’s testing products in 19 Middle Eastern and North African countries.

[Personal Genome Diagnostics] licenses genome mapping tech from [Johns Hopkins]

Thu, 14 Mar 2013 19:02:00 -0400

[Johns Hopkins University] has granted [Personal Genome Diagnostics Inc.] (PGDx; cancer genome analysis) exclusive rights to its patented Digital Karotyping (DK) genome mapping technology.

[NewBridge] gets AfMET rights to [Verinata]'s {verifi} prenatal test

Fri, 08 Mar 2013 19:01:07 -0500

[Illumina Inc.]’s [Verinata Health Inc.] (cell-free fetal DNA prenatal diagnostics) has granted [NewBridge Pharmaceuticals Ltd.] exclusive rights to market in the Middle East, Turkey, Africa, and Caspian regions (AfMET countries) its {verifi} noninvasive prenatal test for high-risk pregnancies.

[Natera] signs on [GenPath], [Quest] to market {Panorama}

Thu, 07 Mar 2013 19:01:00 -0500

[Natera Inc.] (prenatal diagnostics) has signed agreements with [Bio-Reference Laboratories Inc.]’s [GenPath Diagnostics] unit and [Quest Diagnostics Inc.] to market its {Panorama} noninvasive prenatal screening test.

[Sera Prognostics] teams up with [Agilent] to create fetal/maternal assays

Thu, 07 Mar 2013 19:01:00 -0500

[Sera Prognostics Inc.] (diagnostics for pregnancy complications) has teamed up with [Agilent Technologies Inc.] to develop proteomic assays to predict complications early in pregnancy.

[Inova Diagnostics] gets IP from [LUMC] to develop RA biomarker

Wed, 27 Feb 2013 19:01:02 -0500

[Werfen Life Group SA]'s [Inova Diagnostics Inc.] (focused on auto-immune diseases) has received exclusive worldwide rights from [Leiden University Medical Center] (LUMC) to technology for detecting antibodies to carbamylated proteins (anti-CarP).

[Abbott] to develop companion diagnostic for [Pharmacyclic]/[Janssen]'s CLL drug

Thu, 21 Feb 2013 19:01:00 -0500

[Abbott Laboratories Inc.] will use its fluorescence in situ hybridization (FISH) technology to develop a companion diagnostic for a chronic lymphocytic leukemia (CLL) drug candidate in development by [Pharmacyclics Inc.] and [Johnson & Johnson]'s [Janssen Biotech Inc.]

[LipoScience] teams up with [Duke University] to develop new heart biomarkers

Fri, 08 Feb 2013 23:23:00 -0500

[LipoScience Inc.] (personalized diagnostics for cardiovascular, metabolic, and other diseases) will collaborate with [Duke University] on identifying cardiovascular risk factors that can be used independently or in conjunction with clinical measures to stratify and manage acute coronary syndrome.

[Carmenta Bioscience] gets option to IP from [Stanford University]

Fri, 08 Feb 2013 23:23:00 -0500

[Stanford University] has granted 2012 university spin-off [Carmenta Bioscience Inc.] (preeclampsia diagnostics) the option (exercisable over the next year) for an exclusive global license to develop tests that can more precisely predict and diagnose preeclampsia.

[The Doctors Laboratory] to co-promote [Ariosa Diagnostics]' {Harmony} prenatal test

Fri, 08 Feb 2013 23:22:15 -0500

Two-year-old molecular diagnostics company [Ariosa Diagnostics Inc.] has licensed clinical pathology firm [The Doctors Laboratory Ltd.] (TDL) co-promotion and distribution rights in the UK to its {Harmony} noninvasive prenatal test for fetal trisomies 13, 18, and 21.

[Alere] exercises option to preeclampsia biomarker from [Miraculins]

Fri, 08 Feb 2013 23:22:14 -0500

[Alere Inc.] has exercised its exclusive option to license fellow diagnostics firm [Miraculins Inc.]’s endoglin biomarker (which is part of the TGF-beta1 receptor complex) for preeclampsia following a collaborative research agreement that was initiated in January 2010.

[PerkinElmer] to co-promote [Verinata Health]'s {verifi} test in the US

Fri, 08 Feb 2013 23:22:00 -0500

[PerkinElmer Inc.] will exclusively co-promote in the US [Verinata Health Inc.]’s (creating cell-free fetal DNA prenatal diagnostics) {verifi}, a noninvasive prenatal test for high-risk pregnancies.

[MolecularMD] receives LKB1 gene rights from four institutions

Wed, 30 Jan 2013 23:25:00 -0500

[MolecularMD Corp.] (molecular diagnostics for cancer) has licensed exclusive rights from four academic institutions to intellectual property surrounding the use of the liver kinase B1 (LKB1) gene in diagnostic, prognostic, and predictive applications for non-small cell lung cancer. IP was contributed by the [Dana-Farber Cancer Institute], [Massachusetts General Hospital], the [University of North Carolina at Chapel Hill] (UNC), and the [University of Texas Southwestern Medical Center].

[Insight] grants more NSCLC biomarker rights to [Qiagen]

Tue, 22 Jan 2013 19:01:00 -0500

Molecular diagnostics firm [Insight Genetics Inc.] has once again signed a deal with [Qiagen NV], this time granting the assay company exclusive worldwide rights to the RET, ROS1, and DEPDC1 lung cancer biomarkers.

[Qiagen] gets option to [Drug Response Dx]'s RA companion diagnostic

Fri, 18 Jan 2013 19:01:00 -0500

As part of its equity investment in [Drug Response Dx GMBH]’s Series A, [Qiagen NV] received an option to license worldwide rights to a companion diagnostic in development for rheumatoid arthritis.

[Qiagen Marseille] gets HSP110 mutation rights from [Inserm Transfert]

Tue, 15 Jan 2013 19:01:00 -0500

[Inserm Transfert SA], the tech transfer division of the [French National Institute for Health (INSERM)], has granted [Qiagen Marseille SA] (formerly Ipsogen; a subsidiary of [Qiagen NV]) worldwide rights to develop new colorectal cancer tests based on mutations of the HSP110 (heat-shock protein 110) gene.

[Dominion Diagnostics] gets rights to [LifeGen]’s substance abuse risk test

Fri, 11 Jan 2013 19:02:00 -0500

[LifeGen Inc.] (also does business as [Reward Deficiency Solution LLC]; DNA assessment tools to personalize medicine and dietary supplements) has licensed [Dominion Diagnostics LLC] (medication and substance abuse lab testing services) exclusive rights to its genetic test which identifies the genetic addiction risk score (GARS), an indicator of a patient’s relative predisposition in demonstrating addictive behaviors.

[Debiopharm] gets rights to one of [Chugai]'s oncology projects

Thu, 10 Jan 2013 19:01:00 -0500

[Roche]’s [Chugai Pharmaceutical Co. Ltd.] has granted Swiss drug in-licenser [Debiopharm Group] exclusive global rights to its preclinical cancer compound FF284 (which Debiopharm has named Debio1347).

[Siemens] to globally market [BioPorto Diagnostics]' {NGAL Test}

Thu, 10 Jan 2013 19:01:00 -0500

[Siemens Healthcare Diagnostics Inc.] will globally market [BioPorto Diagnostics]’ (immunoassays) {NGAL Test} for kidney injury.

[Novartis]' [Genoptix] gets rights to NPM1 from [Trovagene]

Wed, 09 Jan 2013 19:01:00 -0500

Diagnostic firm [Trovagene Inc.] has licensed [Novartis AG]’s [Genoptix Inc.] (cancer tests) a nonexclusive global license to use nucleophosmin protein (NPM1) in its research and clinical testing services for acute myelogenous leukemia (AML).

[HTG] gets rights to [PROOF Centre]'s COPD prognostic test

Thu, 13 Dec 2012 19:01:00 -0500

Gene expression profiling firm [HTG Molecular Diagnostics Inc.] has received exclusive rights to market the non-profit [Centre of Excellence Prevention of Organ Failure]’s (PROOF Centre; blood tests for chronic organ diseases) diagnostic for the prognosis of COPD patients that suffer from frequent exacerbations.

[Stanford University] licenses immune response technology to [Atreca]

Thu, 13 Dec 2012 19:01:00 -0500

[Stanford University] has granted start-up [Atreca Inc.] (cancer and infectious and autoimmune disease therapeutics and vaccines) an exclusive license to its {Immune Repertoire Capture} sequencing technology for all fields of use.

[Abbott], [BioView] collaborate in tests for NSCLC

Fri, 30 Nov 2012 19:01:00 -0500

Public Israeli cell imaging equipment maker [BioView Ltd.] will develop its {Duet} automated scanner, which can detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in advanced non-small cell lung cancer (NSCLC) patients, for use with [Abbott Laboratories Inc.]’s {Vysis ALK Break Apart FISH Probe Kit}.

[Quanterix] licenses {Simoa} technology to [bioMerieux]

Tue, 20 Nov 2012 19:02:00 -0500

[Quanterix Corp.] (specializes in single-molecule analysis) has licensed [Institut Merieux]’s [bioMerieux SA] exclusive worldwide rights to use its {Simoa} technology in clinical laboratories and for industrial applications.

[Pathology] gets rights to [CombiMatrix]'s products of conception tests

Fri, 09 Nov 2012 19:01:00 -0500

[Pathology Inc.] (laboratory that performs various women’s health tests) has been granted exclusive marketing and distribution rights to molecular diagnostics company [CombiMatrix Corp.]’s chromosomal microarray tests for the products of conception (POC) testing markets in California and Nevada, and the St. Louis and Chicago metropolitan areas. The deal covers the next two years.

[ImaginAb], [Lundbeck] to co-develop CNS biologics and imaging agents

Fri, 09 Nov 2012 19:01:00 -0500

[H. Lundbeck AS] and [ImaginAb Inc.] (molecular imaging employing antibody fragments) have agreed to co-develop biological drug candidates and imaging agents for neurological diseases.

[Abaxis] licenses [Abbott POC] rights to sell {Piccolo Xpress}

Thu, 01 Nov 2012 19:01:00 -0400

[Abaxis Inc.] has licensed fellow POC blood analysis systems company [Abbott Point of Care] exclusive rights to distribute and sell its {Piccolo Xpress} clinical chemistry system and product line of single-use reagent discs in the US, China, and Hong Kong for the next five years, renewable for one-year periods.

[LabCorp] gets US rights to [Sequella]'s {B-Smart} technology

Thu, 25 Oct 2012 19:01:00 -0400

Antibiotics developer [Sequella Inc.] has licensed [Laboratory Corp. of America Holdings] (LabCorp) rights to use its {B-Smart} technology in developing a laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis.

[Iverson Genetic Diagnostics] gets rights to [Johns Hopkins]' cardiovascular/infertility diagnostics

Tue, 23 Oct 2012 19:01:00 -0400

[Iverson Genetic Diagnostics Inc.] has licensed exclusive rights to [Johns Hopkins University School of Medicine]’s molecular diagnostics to assess cardiovascular risk in both men and women and to determine a woman’s risk of infertility.

[DiaSorin] gets license to two [AbD Serotec] antibodies

Thu, 18 Oct 2012 19:01:00 -0400

[MorphoSys AG]’s [AbD Serotec] division has licensed Italian diagnostics firm [DiaSorin SPA] rights to two {HuCAL}-generated antibodies for use in clinical assays for infectious disease testing.

[Amarantus] takes option on Alzheimer’s diagnostic from [Memory Dx]

Wed, 17 Oct 2012 19:01:00 -0400

Through the end of 2012, [Amarantus BioSciences Inc.] (developing CNS and cardiac therapeutics and tests) has received rights to exclusively option diagnostics company [Memory Dx LLC]’s {LymPro} Alzheimer’s disease (AD) assay.

[Roche Diagnostics] to develop companion tests for drugs in development at [AZ]/[MedImmune]

Thu, 11 Oct 2012 19:01:00 -0400

[Roche Diagnostics Corp.] and its contingency of diagnostics business units have agreed to design companion tests that [AstraZeneca PLC] and its [MedImmune LLC] division will use in their drug development activities. The diagnostics are for candidates in all of AZ’s therapeutic areas of focus: gastrointestinal, infectious, and cardiovascular diseases, neuroscience, respiratory conditions, inflammation, and oncology.

[Strand Life Sciences] gets Indian and South Asian rights to [Trovagene]'s HPV test

Thu, 11 Oct 2012 19:01:00 -0400

Public US diagnostics company [Trovagene Inc.] has licensed Indian genomics firm [Strand Life Sciences Pvt. Ltd.] rights to develop and commercialize its urine-based human papillomavirus (HPV) test in India and South Asia.

[Curetis] signs two exclusive distributors for its {Unyvero} platform and pneumonia diagnostic

Sat, 01 Sep 2012 00:00:00 -0400

[Curetis AG] (molecular diagnostics) has signed two exclusive distribution agreements within a day of each other for the {Unyvero} platform and {Unyvero} P50 pneumonia application. [Mediphos Group BV]’s [Mediphos Medical Supplies BV] will distribute the products in the Netherlands and [BioLine LLC] will handle Russia, Ukraine, Kazakhstan, and Belorus.

[Lepu Medical] to market [Qiagen]'s {ESEQuant} lateral flow system in China

Sat, 01 Sep 2012 00:00:00 -0400

[Lepu Medical Technology (Beijing) Co. Ltd.] has received Chinese marketing rights to [Qiagen NV]’s {ESEQuant} lateral flow system, which will be sold for use in emergency rooms alongside Lepu’s cardiac marker tests to diagnose acute myocardial infarction.

[Islet Sciences] gets IP from [Winthrop University Hospital]

Sat, 01 Sep 2012 00:00:00 -0400

[Islet Sciences Inc.] (transplantation therapy for diabetics) has licensed exclusive rights to technology from [Winthrop University Hospital].

[GeneCentric] licenses key diagnostic technologies from [UNC Chapel Hill]

Sat, 01 Sep 2012 00:00:00 -0400

Molecular diagnostics start-up [GeneCentric Diagnostics Inc.] has licensed from the [University of North Carolina at Chapel Hill] exclusive rights to two technologies that will become the backbone for the company’s work in cancer diagnostics development.

[Arch Biopartners] gets option to [University of Alberta]'s IBS diagnostic technology

Sat, 01 Sep 2012 00:00:00 -0400

Public Canadian biotech [Arch Biopartners Inc.] received a one-year option to acquire intellectual property relating to an irritable bowel syndrome diagnostic from the [University of Alberta].

[Axial Biotech] sells {ScoliScore} to [Transgenomic]